Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on understanding the best treatment approaches of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Todd Bauer as the primary speaker and Dr. Ullas Batra as a moderator who will share the important facts associated with treatment approaches for management of ALK positive lung cancer.
Dr. Todd Bauer has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, a discussion on all possible treatment approaches and their pros, cons are discussed.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
2.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
3.
FDA approves rivanetin as the first-line treatment for lung cancer.
4.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
5.
Radiotherapy after mastectomy can be avoided, study finds
1.
Uncovering the Mystery of the Sessile Serrated Adenoma
2.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
3.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
4.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
5.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation